We will like to share with you the following articles by HSA:
(Click the title of the article to read more)
HSA would also like to update healthcare professionals on a fee revision for health products (effective 2 April 2019). These fees, which are incurred by the industry, form a small proportion of the overall cost in bringing health products into the market. Please refer to the attached addendum or HSA’s website for more information.
The news bulletin is posted on the MOH Health Professional Portal and HSA’s website.
- Adverse Drug Reaction News; Sep 2018 Vol.20 No.2
- Regulatory Fee Revision for Health Products
- HSA Update on Valsartan
